Status:
COMPLETED
NGAL and Renal Resistive Index in the Diagnosis and Prognosis of Sepsis-associated AKI
Lead Sponsor:
Inonu University
Conditions:
Sepsis
Acute Kidney Injury
Eligibility:
All Genders
18-70 years
Brief Summary
AKI develops frequently in patients hospitalized in the intensive care unit, and the biggest risk factor is sepsis. Creatine, which is traditionally used in the diagnosis of AKI, is affected by many f...
Detailed Description
In this prospective cross-sectional study, the diagnosis of sepsis (infection+SOFA≥2) and septic shock (lactate\>2 in patients with sepsis and vasopressor requirement to keep mean arterial pressure ab...
Eligibility Criteria
Inclusion
- sepsis
- septic shock
Exclusion
- Weak abdominal echogenicity age \< 18, other conditions causing shock (hypovolemic, cardiogenic, neurogenic), having a life expectancy of less than 24 hours, pregnancy, vasospastic disease, intraperitoneal pressure \> 15 mm Hg, obstructive renal failure or suspected, presence of arrhythmia, presence of renal artery stenosis, kidney transplant patients presence of kidney tumor patients receiving dialysis treatment, solitary kidney and other kidney abnormalities, presence of coronary artery disease, presence of acute mesenteric ischemia, Those who have been using drugs that inhibit angiotensin converting enzyme (ACE) and angiotensin receptor blockers for the last 48 hours, Patients with severe acute or chronic renal failure defined as glomerular filtration rate (GFR) \< 30 ml/min/1.73 m2
Key Trial Info
Start Date :
May 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 11 2022
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT05374759
Start Date
May 11 2022
End Date
December 11 2022
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ayse Belin B OZER
Malatya, Turkey (Türkiye)